. Author manuscript; available in PMC: 2017 May 1.

Published in final edited form as: Adv Healthc Mater. 2016 Apr 20;5(10):1121–1140. doi: 10.1002/adhm.201501019

Table 4.

Biodegradable stents developed or under development (as per Iqbal et al.^[31b] and Boland et al. ^[59])

Stent	Manufacturer	Material	Coating	Drug	Strut thickness [μm]	Absorption time [month]
Polymeric
^a Igaki-Tamai	Kyto Medical	PLLA	None	None	170	24
^d ABSORB BVS 1.0	Abbott Vascular	PLLA	PDLLA	Everolimus	156	18–24
^a ABSORB BVS 1.1	Abbott Vascular	PLLA	PDLLA	Everolimus	156	18–24
^a ABSORB GT1	Abbott Vascular	PLLA	None	Everolimus	156	18–24
^a DeSolve	Elixir	PLLA	None	Myolimus	150	12–24
^d Ideal BTI	Xenogenics	PLLA	Salicylate	Sirolimus	200	6–9
^pc Ideal BioStent	Xenogenics	SA/AA	Salicylate	Sirolimus	175	12
^d REVA	REVA Medical	PTD-PC	None	None	200	24
^c ReZolve	REVA Medical	PTD-PC	None	Sirolimus	200	4–6
^c Fantom	REVA Medical	PTD-PC	None	NA	114–228	24
^a ART 18AZ	ART	PDLLA	None	None	170	3–6
^c Fortitude	Amaranth	PLLA	None	None	150–200	3–6
^pc Xinsorb	Huaan Biotech	PLLA	NA	Sirolimus	160	NA
^pc Acute BRS	Orbus Neich	PLLA, PLDA-ECL	NA	EPC, sirolimus	150	NA
Metallic
^d AMS 1.0	Biotronik	Mg alloy	None	None	165	<4
^d DREAMS-1	Biotronik	Mg alloy	None	Paclitaxel	120	9
^c DREAMS-2	Biotronik	Mg alloy	PLLA	Sirolimus	125	9

with obtained market approval in Europe,

in clinical trials,

discontinued,

^pc

used in pre-clinical trials.